BioNTech presents positive phase 1/2 data for CAR-T cell therapy candidate
<i>"The data show encouraging signs of clinical activity and an increased persistence of cancer-specific CAR-T cells when combined with CARVac."</i><p>Not sure why this is all that interesting to HN.  It's a very early trial and the outcome is "encouraging".<p>Other than a proof of concept that it <i>might work</i>, there is nothing here.